Nesina, Vipdomet(alogliptin)
Incresync, Kazano, Nesina, Oseni, Vipdomet, Vipidia (alogliptin) is a small molecule pharmaceutical. Alogliptin was first approved as Nesina on 2013-01-25. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Nesina
CombinationsKazano, Oseni
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alogliptin benzoate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NESINA | Takeda | N-022271 RX | 2013-01-25 | 3 products, RLD, RS |
Alogliptin benzoate
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KAZANO | Takeda | N-203414 RX | 2013-01-25 | 2 products, RLD, RS |
Alogliptin benzoate
+
Pioglitazone hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OSENI | Takeda | N-022426 RX | 2013-01-25 | 4 products, RLD |
Show 1 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Alogliptin Benzoate, Nesina, Takeda Pharms Usa | |||
| 8697125 | 2029-06-16 | DP | |
| 7807689 | 2028-06-27 | DS, DP | U-1337 |
| 8173663 | 2025-12-02 | U-1338 | |
| 8288539 | 2025-03-15 | DP | |
| Alogliptin Benzoate / Pioglitazone Hydrochloride, Oseni, Takeda Pharms Usa | |||
| 8637079 | 2029-06-04 | DP | |
| Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa | |||
| 8900638 | 2029-05-24 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD09: Pioglitazone and alogliptin
— A10BD13: Metformin and alogliptin
— A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
— A10BH04: Alogliptin
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | 9 | 14 | 10 | 12 | 40 |
| Alcoholic fatty liver | D005235 | K70.0 | — | — | — | 1 | — | 1 | |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | 1 | — | 1 | |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 14 | — | 1 | 17 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALOGLIPTIN |
| INN | alogliptin |
| Description | Alogliptin is a piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. It has a role as an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor and a hypoglycemic agent. It is a nitrile, a member of piperidines, a member of pyrimidines and a primary amino compound. It is a conjugate base of an alogliptin(1+). |
| Classification | Small molecule |
| Drug class | dipeptidyl aminopeptidase-IV inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O |
Identifiers
| PDB | 3G0B |
| CAS-ID | 850649-61-5 |
| RxCUI | 1368001 |
| ChEMBL ID | CHEMBL376359 |
| ChEBI ID | 72323 |
| PubChem CID | 11450633 |
| DrugBank | DB06203 |
| UNII ID | JHC049LO86 (ChemIDplus, GSRS) |
Target
Agency Approved
DPP4
DPP4
Organism
Homo sapiens
Gene name
DPP4
Gene synonyms
ADCP2, CD26
NCBI Gene ID
Protein name
dipeptidyl peptidase 4
Protein synonyms
ADABP, ADCP-2, Adenosine deaminase complexing protein 2, CD26, Dipeptidyl peptidase IV, dipeptidylpeptidase 4, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2), DPP IV, Gly-Pro naphthylamidase, Post-proline dipeptidyl aminopeptidase IV, T-cell activation antigen CD26, TP103, Xaa-Pro-dipeptidylaminopeptidase
Uniprot ID
Mouse ortholog
Dpp4 (13482)
dipeptidyl peptidase 4 (P28843)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Nesina - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,211 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kazano, Oseni
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,316 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more